NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

Anteris Technologies Global Corp. (AVR) Stock Analysis

Anteris Technologies Global Corp. (AVR) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AVR

$6.01

−$0.28 (−4.45%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AVR with… →

AVR Key Statistics

As of Oct 21, 2026
Trading
Open
$6.42
Previous Close
$6.29
Day's Range
5.99–6.42
52-Week Range
3.30–11.06
Volume
1.39M
Valuation
Market Cap
$585.73M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
261.25
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.95
Financials (FY)
Revenue (FY)
$2.73M−14.56%
Net Income (FY)
−$46.02M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
97.46M
1-Year Return
−5.35%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
975.74K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AVR closed at $6.01, −5.35% over 1 year.

Anteris Technologies Global Corp. (AVR) has a market capitalization of $585.73M.

In fiscal 2023, AVR reported revenue of $2.73M.

AVR Stock Return by Calendar Year

Anteris Technologies Global Corp. (AVR) return since Dec 2024: what $10,000 became

1 year
$10,000 $9,465
−5.35%
Since Dec 2024
$10,000 $10,732
+7.32%

If you had invested $10,000 in Anteris Technologies Global Corp. (AVR) at the close on December 13, 2024, the earliest close on record here, it would have been worth $10,732 at the close on October 21, 2026: +7.32% in total, +3.89% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+20.44%
2025−10.57%
2024 (partial year)−0.36%

As of October 21, 2026.

AVR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2023$2.73M−$46.02M−1,682.8%
2022$3.20M−$30.56M−954.9%
2021$5.83M−$17.17M−294.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2023$2.73M$876.80K−$46.66M−$46.02M−1,682.8%
2022$3.20M$298.38K−$31.49M−$30.56M−954.9%
2021$5.83M$1.91M−$16.32M−$17.17M−294.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2023.

AVR Valuation vs Medical Devices Median

Median of 145 stocks
MetricAVRMedical Devices medianvs median
P/S ratio261.252.53103.3x the median

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Anteris Technologies Global Corp. (AVR) at $585.73M. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 174 employees.

AVR last closed at $6.01 on October 21, 2026. That is −$0.28 (−4.45%) against the previous close. The 52-week range on file runs from $3.30 to $11.06. The latest close sits 82.12% above that 52-week low.

Financial Health

Fiscal 2023 revenue came to $2.73M. That is −14.56% against the prior fiscal year, when revenue was $3.20M. The same year closed with a net loss of $46.02M. Trailing earnings per share are −1.95.

Across the 3 fiscal years on file, revenue moves from $5.83M in 2021 to $2.73M in 2023. Of those 3 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 261.25. On price-to-sales that is 103.3 times the Medical Devices median of 2.53. The medians here are taken across 145 Medical Devices companies that report the metric.

Daily returns over the trailing 1 year annualize to a volatility of 64.38%. Over the trailing twelve months the total return is −5.35%. The stored price history starts on December 13, 2024, and the total return since then is +7.32%.

Growth & Income

The record shows no dividend for AVR.

The record holds one complete calendar year, 2025, which returned −10.57%. So far in 2026 the total return is +20.44%.

Peer Comparison

Anteris Technologies Global Corp. (AVR) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Anteris Technologies Global Corp. AVR $585.73M —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. Anteris Technologies Global Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Anteris Technologies Global Corp.

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Visit website →